Overview
The Union Minister of State (Independent Charge) for Science & Technology, Dr Jitendra Singh, inaugurated Phase‑III of the BRCP on 15 July 2026. The new phase brings a total outlay of ₹1,500 crore, with ₹1,000 crore from the DBT and ₹500 crore from the UK‑based Wellcome Trust. The programme aims to build a world‑class biomedical research workforce and boost India’s emerging bioeconomy.
Key Developments
- Phase‑III approved by the Union Cabinet, ensuring continuous fellowships and research grants.
- Funding split: ₹1,000 crore from DBT and ₹500 crore from Wellcome Trust.
- More than 500 researchers have been supported since 2008 across 200+ institutions.
- Programme now emphasizes interdisciplinary, team‑based research to translate discoveries into health technologies.
- Calls for greater participation of philanthropic bodies and industry to sustain innovation.
Important Facts
The bioeconomy, defined as the economic activity derived from scientific and technological advances in biology, has grown from USD 10 billion in 2014 to over USD 195 billion in 2025 and is projected to reach USD 300 billion by 2030. India now hosts roughly 12,000 biotechnology startups and is among the world’s leading vaccine manufacturers. The DBT‑Wellcome Trust India Alliance administers the BRCP, linking Indian scientists with global expertise.
Exam Relevance
Understanding the BRCP helps aspirants answer questions on:
- India’s strategy to develop a biotechnology‑led economy.
- Public‑private‑philanthropic partnerships in scienc